offline
Five Prime Jumps on Progress in Gastric Cancer Drug Trial
Five Prime Therapeutics soared after it said its gastric-cancer treatment met all three of its efficacy endpoints in a Phase 2 trial.
Five Prime Therapeutics (FPRX) - Get Report soared on Wednesday after the biotech said bemarituzumab, its treatment for gastric cancer, met all three of its efficacy endpoints in a Phase 2 trial.
Shares of the South San Francisco company at last check quadrupled to $20.88.
"These results bring us one step closer to the first potential targeted therapy for advanced gastric cancer in over a decade," Helen Collins, a physician who is executive vice president and chief medical officer, said in a statement....
https://www.thestreet.com/investing/stoc..._ven=YAHOO
Five Prime Therapeutics soared after it said its gastric-cancer treatment met all three of its efficacy endpoints in a Phase 2 trial.
Five Prime Therapeutics (FPRX) - Get Report soared on Wednesday after the biotech said bemarituzumab, its treatment for gastric cancer, met all three of its efficacy endpoints in a Phase 2 trial.
Shares of the South San Francisco company at last check quadrupled to $20.88.
"These results bring us one step closer to the first potential targeted therapy for advanced gastric cancer in over a decade," Helen Collins, a physician who is executive vice president and chief medical officer, said in a statement....
https://www.thestreet.com/investing/stoc..._ven=YAHOO
__________________
